Free Trial

Allakos (ALLK) Stock Forecast & Price Target

Allakos logo
$1.16 -0.02 (-1.69%)
(As of 11/15/2024 ET)

Allakos - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
2
Buy
2

Based on 5 Wall Street analysts who have issued ratings for Allakos in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 1 has given a sell rating, 2 have given a hold rating, and 2 have given a buy rating for ALLK.

Consensus Price Target

$1.67
43.68% Upside
According to the 5 analysts' twelve-month price targets for Allakos, the average price target is $1.67. The highest price target for ALLK is $3.00, while the lowest price target for ALLK is $1.00. The average price target represents a forecasted upside of 43.68% from the current price of $1.16.
Get the Latest News and Ratings for ALLK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Allakos and its competitors.

Sign Up

ALLK Analyst Ratings Over Time

TypeCurrent Forecast
11/17/23 to 11/16/24
1 Month Ago
10/18/23 to 10/17/24
3 Months Ago
8/19/23 to 8/18/24
1 Year Ago
11/17/22 to 11/17/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$1.67$1.67$1.67$11.36
Forecasted Upside43.68% Upside156.41% Upside142.60% Upside500.91% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

ALLK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALLK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Allakos Stock vs. The Competition

TypeAllakosMedical CompaniesS&P 500
Consensus Rating Score
2.20
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside43.68% Upside28,534.31% Upside9.86% Upside
News Sentiment Rating
Positive News

See Recent ALLK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/26/2024JMP Securities
2 of 5 stars
 Reiterated RatingMarket Outperform ➝ Market Outperform$3.00 ➝ $3.00+435.61%
7/18/2024Jefferies Financial Group
2 of 5 stars
 Lower TargetHold ➝ Hold$1.50 ➝ $1.00+23.90%
6/20/2024Cantor Fitzgerald
3 of 5 stars
J. Kim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
1/17/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$1.50 ➝ $1.00-15.97%
12/18/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/7/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$22.00+307.41%
3/7/2023Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$22.00+307.41%
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$6.00 ➝ $8.00+9.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:42 PM ET.


ALLK Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Allakos is $1.67, with a high forecast of $3.00 and a low forecast of $1.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There is currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.

According to analysts, Allakos's stock has a predicted upside of 43.68% based on their 12-month stock forecasts.

Allakos has been rated by research analysts at JMP Securities in the past 90 days.

Analysts like Allakos less than other "medical" companies. The consensus rating for Allakos is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALLK compares to other companies.


This page (NASDAQ:ALLK) was last updated on 11/16/2024 by MarketBeat.com Staff
From Our Partners